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bpcummings@ucdavis.eduAbstractDexamethasone has well-described effects to induce insulin resistance and increase insulin
secretion. Herein, we examined potential contributors to the effect of dexamethasone to
increase insulin secretion in rhesus macaques. Six male rhesus macaques received daily
injections of either saline or dexamethasone (0.25 mg/kg i.m. for 7 days) in random order
with 3 weeks between treatments. At the end of the treatment period, animals were fasted
overnight and underwent a feeding study the next day, during which blood samples were
taken before and for 60 min after a meal in order to assess islet hormone and incretin
secretion. Dexamethasone induced marked increases in fasting plasma insulin, glucagon,
leptin, and adiponectin concentrations (P!0.05). Surprisingly, the glycemic response after
meal ingestion was decreased twofold during dexamethasone treatment (P!0.05).
Dexamethasone-treated animals exhibited a significant increase in both insulin and glucose-
dependent insulinotropic polypeptide (GIP) secretion during the feeding study (P!0.05).
However, glucagon-like peptide-1 secretion was significantly lower in dexamethasone-
treated animals compared with controls (P!0.01). Fasting and meal-stimulated pancreatic
polypeptide concentrations (an index of the parasympathetic input to the islet) did not differ
between saline and dexamethasone treatments. However, the proinsulin:insulin ratio was
decreased throughout the feeding study with dexamethasone treatment suggesting an
improvement of b-cell function (P!0.05). In conclusion, the maintenance of euglycemia and
reduction of postprandial glycemia with short-term dexamethasone treatment appears to
be due to the marked elevations of fasting and meal-stimulated insulin secretion.
Furthermore, increases in postprandial GIP secretion with dexamethasone treatment appear
to contribute to the effect of dexamethasone treatment to increase insulin secretion.Key Words
" insulin resistance
" Dexamethasone
" GIP
" rhesus macaqueJournal of Endocrinology
(2013) 216, 207–215
Jo
u
rn
a
l
o
f
E
n
d
o
cr
in
o
lo
g
y
Research B P CUMMINGS and others Dexamethasone increases insulin
secretion
216 :2 208IntroductionDexamethasone is a synthetic glucocorticoid that is
commonly used in the treatment of numerous medical
conditions due to its anti-inflammatory and immuno-
suppressive properties (Rosen & Miner 2005). However,
chronic exposure to high levels of circulating exogenous
and endogenous glucocorticoids is associated with several
side effects, including insulin resistance (Vegiopoulos &
Herzig 2007). For example, patients with enhanced
endogenous glucocorticoid production (Cushing’s syn-
drome) often exhibit hyperglycemia, hyperinsulinemia,
and hepatic steatosis (Howlett et al. 1985).
Under normal physiological conditions, glucocorti-
coids function to protect against hypoglycemia during
times of acute stress and/or reduced energy intake.
Glucocorticoids increase circulating glucose concen-
trations through several mechanisms; specifically, they
increase hepatic glucose production (McMahon et al.
1988), decrease peripheral glucose uptake (Weinstein
et al. 1998, Sakoda et al. 2000), and promote the break-
down of muscle and fat to provide substrates for
gluconeogenesis (Divertie et al. 1991, Hasselgren 1999).
While long-term glucocorticoid treatment is often
associated with derangements of glucose homeostasis,
short-term glucocorticoid treatment (i.e. !2 weeks
exposure) generally does not result in marked glycemic
alterations (e.g. diabetes). Specifically, glucose homeo-
stasis has been proposed to be maintained during short-
term glucocorticoid treatment by the induction of
hyperinsulinemia (Karlsson et al. 2001, Nicod et al.
2003), which is supported by both clinical studies in
humans and studies in rodents demonstrating marked
increases in glucose-stimulated insulin secretion during
short-term glucocorticoid treatment (Beard et al. 1984,
Rafacho et al. 2010a). However, the mechanism(s) by
which dexamethasone causes these marked elevations of
insulin secretion are not well defined.
Longer term studies in rodents suggest that the
hyperinsulinemic effect of glucocorticoids is due to an
enhancement of b-cell mass and function (Ogawa et al.
1992, Rafacho et al. 2010b). However, there are little data
on the mechanisms responsible for the observed enhance-
ment of insulin secretion in the short term. We
hypothesized that dexamethasone may enhance post-
prandial insulin secretion by increasing meal-stimulated
incretin hormone secretion and/or by increasing
parasympathetic input to the pancreas. The incretin
hormones, glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP), are producedhttp://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-12-0459 Printed in Great Britainand secreted by gastrointestinal enteroendocrine cells in
response to the ingestion of nutrients (Baggio & Drucker
2007). Specifically, GLP-1 is produced by L-cells, primarily
located in the distal gastrointestinal tract, and GIP is
produced by K-cells, mostly located in the duodenum and
proximal jejunum. As incretins, these hormones potenti-
ate glucose-stimulated insulin secretion. Furthermore,
studies in rodents suggest that both these hormones
promote increases in insulin synthesis and b-cell mass
(Brubaker & Drucker 2004, Kim et al. 2005).
Furthermore, previous studies in rodents have
suggested that the effect of glucocorticoids to increase
insulin secretion is mediated, in part, by the parasympa-
thetic nervous system (Angelini et al. 2010). Indeed,
Fletcher & McKenzie (1988) demonstrated that adminis-
tration of a parasympatholytic (atropine) to obese Zucker
rats receiving corticosterone reduced the effect of cortico-
sterone to enhance glucose-stimulated insulin secretion.
Thus, in order to investigate the role that incretin
hormones and parasympathetic input to the pancreas play
in the effect of short-term dexamethasone treatment to
increase glucose-stimulated insulin secretion, we per-
formed feeding studies in rhesus macaques after a 7-day
course of dexamethasone treatment.Materials and methods
Animals and catheter implantation
Six adult male rhesus macaques (Macaca mulatta) ranging
6–14 years of age (meanGS.E.M., 10.5G1.2 years) and
8.7–12.5 kg in body weight (meanGS.E.M., 10.7G0.6 kg)
were used for the studies. A physical examination,
complete blood count, and serum biochemistry panel
were performed for each animal before animals were
selected and placed on the study. The animals were
acclimated to several hours of chair restraint before the
study. At least 1 week before the study, an iliac or femoral
artery was catheterized under ketamine/isoflurane
anesthesia with a polyurethane catheter connected to a
subcutaneous vascular access port (Access Technologies,
Skokie, IL, USA), as described previously (Havel & Valverde
1996). Animals were housed in the American Association
for Accreditation of Laboratory Animal Care accredited
facilities at the California National Primate Research
Center in accordance with standards established by the
U.S. Animal Welfare Act and the Institute of Laboratory
Animal Resources. The experimental protocols were
approved by the Institutional Animal Care and UsePublished by Bioscientifica Ltd.
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216 :2 209Committee at the University of California, Davis, and the
California National Primate Research Center and were
conducted in accordance with guidelines of the National
Research Council’s Guide for the Care and Use of
Laboratory Animals.Feeding protocol
Each animal was studied twice in random order: 1) during
saline treatment and 2) during dexamethasone treatment
(0.25 mg/kg per day i.m. for 7 days). The studies were
performed at least 21 days apart. Animals received
treatment for 7 days and then were fasted overnight and
underwent a feeding study the following day as described
previously (D’Alessio et al. 2001). Animals were placed in
restraint chairs at least 1 h before initiation of the feeding
study. Three baseline blood samples (3 ml each) were
drawn from the arterial port at K15, K10, and 0 min.
Animals were then fed food at 0 min and blood samples
were drawn at 2 and 5 min after feeding food. Animalswere
then fed a meal of one banana, half an apple, and three
monkey chow biscuits (Purina 5047, Ralston Purina Co.,
St Louis,MO,USA). Blood samples were then collected at 2,
5, 10, 15, 30, 45, and 60 min after the animals began to eat.
In the subsequent experiment, the animals were fed the
same amount and type of food that was consumed by
that animal during the initial experiment. Therefore, the
amount of energy consumed and the macronutrient
composition of themeal did not differ between experiments.
Themeals contained an average of 38.6G5.3 g carbohydrate,
5.0G2.0 g protein, and 1.7G0.4 g fat. The approximate
macronutrient composition of the meal was 80, 13, and
7% carbohydrate, protein, and fat respectively.Plasma assays
Blood samples collected for measurement of plasma
glucose concentrations were drawn and placed in
heparin-treated tubes. Blood samples for measurement of
circulating insulin, pancreatic polypeptide, total GIP, and
total GLP-1 concentrations were placed in tubes
containing ethylenediamine tetraacetate and aprotinin
(Sigma). Plasma glucose concentrations were measured by
the glucose oxidase method with a glucose analyzer
(Beckman Coulter, Inc., Fullerton, CA, USA). Plasma
insulin concentrations were measured by RIA (Linco,
St Louis, MO, USA). Plasma pancreatic polypeptide, GLP-1,
and GIP concentrations were measured by RIA, as described
previously (Gingerich et al. 1978,Morgan et al. 1978,Orskov
& Holst 1987).http://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-12-0459 Printed in Great BritainStatistical analysis
Data are presented asmeanGS.E.M. Statistical analyses were
performed using GraphPad Prism 4.00 for Windows
(GraphPad Software, San Diego, CA, USA). Fasting plasma
data were analyzed by one-factor ANOVA with Bonferro-
ni’s multiple comparison posttest analyses. Data from the
feeding studies were analyzed by Student’s t-test of the
area under the curve (AUC). Differences were considered
significant at P!0.05.Results
Fasting metabolites
Fasting plasma cortisol concentrations dropped to below
the detection limit of the cortisol assay throughout the
7-day course of dexamethasone treatment, due to negative
feedback by the exogenous glucocorticoid on the
hypothalamic–pituitary–adrenal axis (Fig. 1A; P!0.001).
Dexamethasone treatment resulted in marked fasting
hyperinsulinemia (control, 102G24 pmol/l; dexametha-
sone, 906G228 pmol/l; P!0.05), reflecting the develop-
ment of insulin resistance. Fasting plasma proinsulin
concentrations were also markedly increased during
dexamethasone administration (Fig. 1B; P!0.01).
However, fasting plasma glucose concentrations were
unchanged during dexamethasone treatment (control,
4.0G0.2 mmol/l; dexamethasone, 4.3G0.2 mmol/l).
Interestingly, fasting plasma glucagon concentrations
increased in a step-wise manner during dexamethasone
treatment (Fig. 1C; P!0.05).
Changes of circulating leptin and adiponectin levels
were also assessed. Similar to what has been reported in
previous clinical studies in humans, dexamethasone
treatment resulted in a significant elevation of fasting
plasma leptin concentrations within 2 days of treatment
(Dagogo-Jack et al. 1997), which persisted over the 7-day
treatment period (Fig. 1D). Fasting plasma adiponectin
concentrations were also significantly elevated with
dexamethasone treatment (control, 355G42 pmol/l;
dexamethasone, 446G36 pmol/l; P!0.05).Postprandial glycemic response
Feeding studies were performed in order to assess the effect
of dexamethasone treatment on glucose homeostasis in
response to a meal. As shown in Fig. 2A, basal fasting
plasma glucose concentrations did not differ with saline or
dexamethasone treatment. Plasma glucose concentrations
did not change during the period in which animals werePublished by Bioscientifica Ltd.
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Figure 1
Fasting plasma hormones. Fasting plasma concentrations of cortisol (A), proinsulin (B), glucagon (C), and leptin (D). CCCP!0.001, CP!0.05 by one-factor
ANOVA, ***P!0.001, *P!0.05 by Bonferroni’s posttest compared with baseline.
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216 :2 210fed food, under either treatment condition. However,
under control conditions, plasma glucose concentrations
rose significantly above baseline concentrations starting
at 10 min after the start of the meal and remained
significantly elevated for the 1-h duration of the feeding
study. By contrast, with dexamethasone treatment,
animals did not exhibit significant increases in circulating
glucose levels until 30 min after the initiation of the
meal. Furthermore, the glucose AUC during the meal
was reduced by w50% with dexamethasone treat-
ment (control, 174G33 mmol/l!60 min, dexamethasone,
79G28 mmol/l!60 min; P!0.05).
As shown in Fig. 2B, insulin concentrations were
markedly elevated with dexamethasone treatment
compared with saline-treated controls at all time points
during the feeding test. Moreover, insulin concentra-
tions did not change from baseline levels under
either treatment condition when animals were shown
food. Under control conditions, circulating insulinhttp://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-12-0459 Printed in Great Britainconcentrations rose significantly above baseline starting
at 15 min after initiation of the meal. However, when
animals were treated with dexamethasone, insulin
concentrations rose significantly above baseline starting
at 20 min after initiation of the meal. Dexamethasone
treatment resulted in approximately a fourfold increase in
the insulin AUC during the meal compared with control
conditions (control, 21 148G5056 pmol/l!60 min; dexa-
methasone, 91 916G19 316 pmol/l!60 min; P!0.01).
Furthermore, the increase in insulin concentrations
from baseline to peak values was approximately threefold
higher with dexamethasone treatment (P!0.05). Thus,
7 days of treatment with dexamethasone markedly
increased both fasting plasma insulin and postprandial
insulin responses.
Glucagon concentrations were approximately three-
fold higher at all time points with dexamethasone
treatment compared with control (Fig. 2C; P!0.01).
Plasma glucagon concentrations decreased after ingestionPublished by Bioscientifica Ltd.
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Figure 2
Postprandial glucose and pancreatic hormone responses. Plasma levels of
glucose (A), insulin (B), and glucagon (C) during a feeding test. CP!0.05 by
Student’s t-test of the AUC.
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216 :2 211of the meal under both control and dexamethasone-
treated conditions. The increase in fasting and postpran-
dial plasma glucagon concentrations with dexamethasone
treatment appears to be a compensatory response to thehttp://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-12-0459 Printed in Great Britainmarked increase in fasting plasma insulin concentrations
and postprandial insulin secretion to prevent the
development of hypoglycemia.
Postprandial proinsulin response
Proinsulin was measured before and during the feeding
studies in order to assess b-cell function. Before the feeding
test, fasting proinsulin concentrations were approxi-
mately threefold higher in dexamethasone-treated
animals compared with controls (P!0.01). Circulating
proinsulin concentrations remained significantly higher
throughout the feeding study when animals had been
treated with dexamethasone (Fig. 3A; P!0.05). The
proinsulin to insulin ratio was calculated as an index of
b-cell function in response to dexamethasone treatment.
The proinsulin-to-insulin ratio was significantly lower in
dexamethasone-treated animals compared with control
conditions throughout the feeding study (Fig. 3B;
P!0.05). Thus, dexamethasone treatment appears to
improve b-cell function.Postprandial incretin response
In order to investigate the potential contribution of
incretins to the enhancement of insulin secretion during
short-term dexamethasone treatment, the GIP and GLP-1
responses during the feeding study were assessed. Fasting
plasma GIP concentrations did not differ between treat-
ments (Fig. 3C). Plasma GIP concentrations increased to
levels greater than fasting at 15 min after initiation of the
meal with both saline and dexamethasone treatment.
Importantly, the AUC for GIP was approximately twofold
greater when animals were receiving dexamethasone
(control, 9519G3041 pmol/l!60 min; dexamethasone,
16 276G4196 pmol/l!60 min; P!0.05), suggesting that
dexamethasone-mediated increases in postprandial GIP
secretion may contribute to the increase in postprandial
insulin secretionobservedduringdexamethasone treatment.
Like GIP, fasting plasma GLP-1 concentrations did not
differ between the treatment groups (Fig. 3D). Plasma
GLP-1 concentrations also increased to levels greater than
baseline at 15 and 20 min after initiation of the meal
during both saline and dexamethasone treatment
respectively. In contrast to GIP, the GLP-1 AUC was signi-
ficantly lower in dexamethasone-treated animals com-
pared with controls (control, 359G101 pmol/l!60 min;
dexamethasone, 130G118 pmol/l!60 min; P!0.01).
Therefore, GLP-1 does not appear to contribute to
the effect of dexamethasone treatment to augment
insulin secretion.Published by Bioscientifica Ltd.
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Figure 3
Postprandial proinsulin, proinsulin:insulin ratio, incretin (GIP and GLP-1),
and pancreatic polypeptide responses. Plasma levels of proinsulin (A), the
plasma proinsulin:insulin ratio (B), and plasma concentrations of GIP (C),
GLP-1 (D), and pancreatic polypeptide (E). CCP!0.01, CP!0.05 by
Student’s t-test of the AUC.
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216 :2 212Postprandial pancreatic polypeptide response
Pancreatic polypeptide was measured during the feeding
studies in order to assess changes of parasympathetic input
to the pancreas. Fasting plasma pancreatic polypeptidehttp://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-12-0459 Printed in Great Britainconcentrations did not differ between treatments (Fig. 2E).
Furthermore, pancreatic polypeptide excursions during
the feeding study did not differ between treatments.
Therefore, changes of parasympathetic input to thePublished by Bioscientifica Ltd.
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216 :2 213pancreas do not appear to contribute to the effects of
dexamethasone administration to increase fasting insulin
concentrations or postprandial insulin secretion.Discussion
In this study, we investigated the role of incretin
hormones and parasympathetic input to the pancreas in
dexamethasone-induced increases in postprandial insulin
secretion in rhesus macaques. Short-term dexamethasone
administration resulted in marked increases in fasting and
postprandial circulating insulin concentrations, allowing
for the maintenance of normoglycemia despite marked
insulin resistance. Dexamethasone treatment also resulted
in a decrease in the proinsulin to insulin ratio, suggesting
an improvement of b-cell function in the short term.
Furthermore, dexamethasone treatment resulted in a
twofold increase in postprandial GIP excursions,
suggesting that increased GIP secretion is a plausible
contributor to the increase in postprandial insulin
secretion observed with administration of exogenous
glucocorticoids.
Similar to previous studies in rodents and clinical
studies in humans, short-term dexamethasone treatment
markedly elevated fasting and postprandial insulin
secretion (Beard et al. 1984, Fletcher & McKenzie 1988,
Rafacho et al. 2010a). This marked increase in meal-
stimulated insulin secretion with dexamethasone treat-
ment likely contributed to the 50% lower glucose
excursions during the feeding test. Of note, the effect of
dexamethasone to increase insulin secretion in vivo is in
contrast to several studies demonstrating that, in vitro,
glucocorticoids such as dexamethasone decrease insulin
secretion (Gremlich et al. 1997). Also, similar to previous
reports, dexamethasone treatment significantly elevated
fasting plasma leptin concentrations (Dagogo-Jack et al.
1997). Leptin has been strongly implicated in having an
important role in the regulation of glucose homeostasis
and thus may have contributed to the maintenance of
normoglycemia indexamethasone-treated rhesusmacaques
(Cummings et al. 2011, Morton & Schwartz 2011).
Previous studies in rodents have shown that gluco-
corticoid administration increases insulin secretion by
enhancing islet secretory capacity (Rafacho et al. 2010a).
Therefore, we measured circulating proinsulin concen-
trations as an index of b-cell function in the fasting and
postprandial states. While fasting and meal-stimulated
proinsulin concentrations were increased with dexa-
methasone treatment, the proinsulin-to-insulin ratio was
significantly lower in dexamethasone-treated animals,http://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-12-0459 Printed in Great Britainsuggesting an improvement of b-cell function during
short-term dexamethasone treatment. This enhancement
of b-cell function may be due to an enhancement of
stimulus secretion coupling, as previously suggested by
two studies in rats (Rafacho et al. 2010a,b).
Notably, both fasting plasma glucagon concentrations
and glucagon levels in the postprandial state were
markedly increased with dexamethasone treatment.
These increases were likely a compensatory response to
protect against the development of hypoglycemia in the
face of marked hyperinsulinemia. Interestingly, a previous
human clinical study in humans by Wise et al. (1973)
demonstrated that dexamethasone administration
increased fasting plasma glucagon concentrations and
glucagon secretion in response to a protein meal in both
lean subjects and in subjects with increased endogenous
glucocorticoid production (i.e. Cushing’s syndrome).
Several mechanisms for glucocorticoid-induced
increases in glucose-stimulated insulin secretion have
been proposed in the literature, including increases in
circulating incretin hormones (Koko et al. 2008) and
enhanced parasympathetic input to the islet (Angelini
et al. 2010). In this study, short-term administration of
dexamethasone resulted in a twofold increase in meal-
stimulated GIP excursions compared with control
conditions, but modestly decreased postprandial GLP-1
excursions. These data are in agreement with previous
work by Koko et al. (2008) demonstrating that 12 days of
treatment with dexamethasone in Wistar rats increased
intestinal K-cell numbers. Of note, fasting plasma GIP
concentrations did not differ between treatments, whereas
fasting plasma insulin concentrations were increased
fourfold with dexamethasone treatment. This suggests
that a mechanism other than GIP action on the b-cell is
responsible for producing fasting hyperinsulinemia
during administration of exogenous glucocorticoids.
These results are also in partial agreement with a recent
study in humans by Jensen et al. (2012) reporting that
5 days of treatment with dexamethasone results in
increased GIP excursions during an oral glucose tolerance
test. However, the observed decrease in GLP-1 excursions
during the feeding study in rhesusmacaques conflicts with
this same study, which also demonstrated significant
increases in GLP-1 excursions during the oral glucose
tolerance test. In fact, GIP and GLP-1 are generally
regulated in parallel; however, in this study, we report a
divergent effect of dexamethasone on GIP and GLP-1
regulation. These differences may be due to species-related
differences in the regulation of incretin hormone
secretion. Furthermore, other causes of insulin resistancePublished by Bioscientifica Ltd.
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216 :2 214have been shown to increase GLP-1 secretion. For
example, a study performed in dogs reported increased
GLP-1 secretion in insulin resistance induced by high-fat
feeding (van Citters et al. 2002). This suggests that
potential differential effects of insulin resistance on
incretin secretion may be dependent on the underlying
etiology of the insulin resistance. Nevertheless, the current
results suggest that increased GIP, but not GLP-1, has a
role in enhancing postprandial insulin secretion during
short-term treatment with dexamethasone in rhesus
macaques. However, a recent study in humans reported
that the insulin secretory response to GIP and GLP-1 is
impaired with experimental insulin resistance induced by
a combination of increased energy intake and predniso-
lone administration for 12 days (Hansen et al. 2012).
Additional studies will be necessary to determine the
physiological role of increases in meal-stimulated GIP
secretion in glucocorticoid-induced insulin resistance.
Several previous studies performed in rodents have
suggested that increased parasympathetic outflow to the
pancreas is an important contributor to the effect of
glucocorticoids to increase insulin secretion (Fletcher &
McKenzie 1988, Angelini et al. 2010). Pancreatic poly-
peptide is an islet hormone known to be closely regulated
by parasympathetic input to the islet in response to
feeding and during insulin-induced hypoglycemia in
rhesus macaques and humans (Schwartz 1988, Havel &
Valverde 1996, Havel & Ahren 1997, Ahren & Holst 2001,
D’Alessio et al. 2001). In this study, we found that
peripheral administration of dexamethasone to rhesus
macaques does not alter fasting or meal-stimulated
pancreatic polypeptide concentrations. Interestingly, a
previous study by Sainsbury et al. (2001) demonstrated
that central but not s.c. administration of dexamethasone
toWistar rats results in increased parasympathetic outflow
to the pancreas and elevated insulin secretion. However,
based on the measurements of pancreatic polypeptide
concentrations in this study, it does not appear that
increased parasympathetic input to the pancreas has a role
in glucocorticoid-mediated increases in insulin secretion
when dexamethasone is administered peripherally.
In conclusion, a 7-day course of dexamethasone
treatment in rhesus macaques produces marked fasting
and postprandial hyperinsulinemia in order to maintain
normal fasting and postprandial glucose homeostasis. The
increase in circulating insulin concentrations appears to
overcompensate for the degree of insulin resistance;
however, this is counteracted by increased glucagon
concentrations in both the fasting and the postprandial
states. The increase in postprandial insulin secretionhttp://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-12-0459 Printed in Great Britainobserved after dexamethasone administration may be
mediated, at least in part, by increases in meal-stimulated
GIP secretion. Increases in parasympathetic input to the
pancreas do not appear to contribute to glucocorticoid-
induced increases in insulin secretion, as pancreatic
polypeptide responses were unchanged during dexa-
methasone treatment. Overall, these findings in non-
human primates provide new information on the
short-term compensatory alterations of pancreatic islet
and incretin hormones occurring in response to short-
term exogenous glucocorticoid administration.
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